IP Verse

Janssen Pharmaceutica competitive analysis

Latest publications and patents of Janssen Pharmaceutica New

Explore the latest publications and patents granted to Janssen Pharmaceutica, showcasing their recent innovations and technological advancements.

Last updated on: Sep 23, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Janssen Pharmaceutica

EP4552698
Jul 30, 2025Methods Of Treating Prostate CancerPublished
EP2234617
Nov 6, 2024Dosing Regimen Associated With Long Acting Injectable Paliperidone EstersPatent Maintained As Amended
EP4005555
May 15, 2024Methods For Ensuring Resuspension Of Paliperidone Palmitate FormulationsGranted And Under Opposition
EP4025188
Jan 10, 2024Dosing Regimens Associated With Extended Release Paliperidone Injectable FormulationsGranted And Under Opposition
EP4025187
Jan 3, 2024Dosing Regimens Associated With Extended Release Paliperidone Injectable FormulationsGranted And Under Opposition
EP3744326
Dec 6, 2023Dosing Regimen For Missed Doses For Long-Acting Injectable Paliperidone EstersGranted And Under Opposition
EP3609497
Oct 12, 2022Combination Therapy For Prostate CancerGranted And Under Opposition
EP3311374
Jul 22, 2020Devices And Methods For Drug Administration And Mixing, And Training Of Proper Techniques ThereforGranted And Under Opposition
EP3280416
Apr 22, 2020Dosing Regimen For Missed Doses For Long-Acting Injectable Paliperidone EstersGranted And Under Opposition
EP3087098
Apr 8, 2020Anti-Vista Antibodies And FragmentsRevoked

Latest oppositions filed by Janssen Pharmaceutica

Explore patent oppositions filed by Janssen Pharmaceutica against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Sep 25, 2025
Patent NumberTitleApplicantOpposition Date

Get instant updates on new opposition filings by the company

EP3291679
Altering Microbial Populations & Modifying MicrobiotaSNIPRSep 14, 2022
EP3481838
Novel Processes For The Production Of OligonucleotidesGLAXOSMITHKLINEMay 19, 2021
EP2588167
Safety Device For A Pre-Filled Syringe And Injection DeviceSANOFI AVENTIS DEUTSCHLANDNov 21, 2018

Latest patents of Janssen Pharmaceutica opposed by its competitors

Explore Janssen Pharmaceutica's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Sep 25, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP2234617
Nov 6, 2024Dosing Regimen Associated With Long Acting Injectable Paliperidone Esters20
EP4005555
May 15, 2024Methods For Ensuring Resuspension Of Paliperidone Palmitate Formulations2
EP4025188
Jan 10, 2024Dosing Regimens Associated With Extended Release Paliperidone Injectable Formulations2
EP4025187
Jan 3, 2024Dosing Regimens Associated With Extended Release Paliperidone Injectable Formulations2
EP3744326
Dec 6, 2023Dosing Regimen For Missed Doses For Long-Acting Injectable Paliperidone Esters9
EP3609497
Oct 12, 2022Combination Therapy For Prostate Cancer3
EP3311374
Jul 22, 2020Devices And Methods For Drug Administration And Mixing, And Training Of Proper Techniques Therefor1
EP3280416
Apr 22, 2020Dosing Regimen For Missed Doses For Long-Acting Injectable Paliperidone Esters8
EP3087098
Apr 8, 2020Anti-Vista Antibodies And Fragments2
EP2968221
Jun 19, 2019Pharmaceutical Composition Of S-Ketamine Hydrochloride2

Latest PTAB cases involving Janssen Pharmaceutica

Discover the latest PTAB cases involving Janssen Pharmaceutica, highlighting their recent legal challenges and patent disputes.

Last updated on: Sep 29, 2025
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Janssen Pharmaceutica

IPR2020-00440Feb 7, 2020MYLAN LABORATORIESJANSSEN PHARMACEUTICAInstitution Denied
IPR2013-00365Jun 19, 2013HOSPIRAJANSSEN PHARMACEUTICALSInstitution Denied

Peer Comparison New

IP litigation analysis comparing Janssen Pharmaceutica with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Sep 25, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases FacedStrategy Type
JANSSEN PHARMACEUTICA154 - 1Defensive
ACCORD HEALTHCARE34 - 4 - Highly Aggressive
GENERICS UK211 - - - Highly Aggressive
TEVA PHARMACEUTICALS20515 - 12Highly Aggressive